本季度信息
昭衍新药公布2026年第一季度业绩，营业收入为3.16亿元，同比增长10.02%。经调整净利润（扣除非经常性损益后）为2.17亿元，同比大幅增长747.11%。整体毛利率约为20.50%，经营利润率约为80.99%。经营活动产生的现金流约1.28亿元，同比提升95.88%。
从成本端来看，销售费用约615万元，占营收比重约1.95%；管理费用约6689万元，占营收比重约21.16%；研发投入约1946万元，占营收比重约6.16%。
业务分项
本季度实验室服务及其他业务贡献净利润为-2846.11万元，同比下降15.13%，主要原因在于行业竞争激烈的滞后影响，导致毛利率处于较低水平。同时，生物资产公允价值变动带来约2.46亿元净收益，是拉动整体净利润增长的关键因素。此外，新签订单金额约9.1亿元，同比上升111.6%，在手订单累计约31亿元，同比增长40.9%，为后续业绩的持续释放提供了较为充足的订单储备。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.